December 2021 - PharmaTimes

December 2021 - PharmaTimes
Published on 5 December 2021

Description:

Inclusion zone – nothing crystallises the need for diversity and inclusion quite like pharma and now we must prescribe it throughout our industry, Review of the Year: pharma, the NHS and patients, Parkinson’s disease and gene therapy, the need for diversity and inclusion in pharma, the results from Clinical Researcher of the Year 2021 – the Americas.

Categories:

PharmaTimes

Preview:

28 articles from this collection:
Cover
Cover
2 - LabCorp Oncology
2 - LabCorp Oncology
3 - From the editor
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020. Taking top-spot in the ranking, Exscientia has almost quadrupled its revenue in the last two years, a remarkable achievement and even more so considering the current climate. Turn to page 20 for an in-depth look at the other companies reaching new heights and what’s fuelling their success.
4-5 - Contents
4-5 - Contents
6 - Medicine News
6 - Medicine News
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - Clinical Researcher of the Year
7 - Clinical Researcher of the Year
8 - Hot or Not
8 - Hot or Not
ViiV Healthcare’s Rukobia (fostemsavir) has received a marketing authorisation in Europe for the treatment of adults with multidrug-resistant HIV-1 infection. The EU has cleared use of the drug in patients who cannot otherwise receive a suppressive antiviral-regimen. Rukobia – a first-in-class HIV attachment inhibitor – is designed to target the first step of the HIV life-cycle. According to ViiV, it shows no cross-resistance to other currently approved antiretroviral classes, offering a new option for patients who are multidrug-resistant and at a higher risk of disease progression or death.
9 - CHIRON / GRIFOLS
9 - CHIRON / GRIFOLS
10 - COVID NEWS
10 - COVID NEWS
The UK government is streaming funds of £18.5 million into four research projects striving to improve understanding of the longer-term effects of COVID-19, known as long COVID.
11
11
12 - SMART PEOPLE INSIGHT: Laetitia Decroix Guilloux
12 - SMART PEOPLE INSIGHT: Laetitia Decroix Guilloux
13 - Addressing implicit bias in clinical trials
13 - Addressing implicit bias in clinical trials
14-15 - Inclusion zone
14-15 - Inclusion zone
16-17 - Why pharma needs to understand population health
16-17 - Why pharma needs to understand population health
18-19 - The UK life sciences sector: 2021 review
18-19 - The UK life sciences sector: 2021 review
20-21 - Maintaining the halo effect
20-21 - Maintaining the halo effect
22-23 - Pharmaceuticals in 2022
22-23 - Pharmaceuticals in 2022
24-25 - Sustainability is the word
24-25 - Sustainability is the word
26-28 - The ecosystem overtakes the producers in pharma and life sciences
26-28 - The ecosystem overtakes the producers in pharma and life sciences
29 - My reflections on 2021:  a year of building the foundations for future growth  By Graeme Duncan, CEO of ADVANZ PHARMA
29 - My reflections on 2021: a year of building the foundations for future growth By Graeme Duncan, CEO of ADVANZ PHARMA
30-31 - The ever-increasing importance of the patient’s voice
30-31 - The ever-increasing importance of the patient’s voice
32-34 - Parkinson’s disease and gene therapy: strategic and operational considerations
32-34 - Parkinson’s disease and gene therapy: strategic and operational considerations
35 - PharmaTimes International Clinical Researcher of the Year 2022
35 - PharmaTimes International Clinical Researcher of the Year 2022
36-37 - Behavioural science
36-37 - Behavioural science
38-39 - Appointments
38-39 - Appointments
40-42 - Patient Files
40-42 - Patient Files
43 - Clinical Researcher of the Year - The Americas
43 - Clinical Researcher of the Year - The Americas
48 - LabCorp
48 - LabCorp